search

Active clinical trials for "Neoplasms"

Results 121-130 of 64586

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies...

Relapsed/Refractory Acute Myeloid Leukemia (AML)

NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.

Recruiting23 enrollment criteria

Safety and Efficacy of OBX-115 in Advanced/Metastatic Melanoma Resistant to Immune Checkpoint Inhibitors...

Tumor SkinMetastatic Melanoma1 more

This is a study to investigate the safety and efficacy of an investigational regimen, OBX-115, in adult participants with advanced/metastatic melanoma.

Recruiting21 enrollment criteria

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine...

MTAP-null Non-Small-Cell Lung CancerMTAP-null Solid Tumors

The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).

Recruiting15 enrollment criteria

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Advanced Renal Cell Carcinoma

This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. The study will plan to enroll 120 eligible patients randomized in a 2:1 fashion to Arm A and Arm B. Patients in all IMDC Risk Groups are included. This study utilizes a Simon's two stage design which is described in the protocol. Patients randomized to Arm A will receive botensilimab in combination with balstilimab. Patients randomized to Arm B will receive ipilimumab in combination with nivolumab. Study treatment on both arms will continue until toxicity, disease progression or a maximum of 96 total weeks (12 weeks induction, 84 weeks maintenance).

Recruiting56 enrollment criteria

Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer

Advanced Colorectal Carcinoma

To clarify the effectiveness and safety of compound kushen injection in the treatment of advanced colorectal cancer.

Recruiting11 enrollment criteria

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

Anal Cancer

To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.

Recruiting16 enrollment criteria

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma...

Relapsed and/or Refractory Multiple MyelomaPlasma Cell Leukemia in Relapse

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia

Recruiting34 enrollment criteria

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University...

Oropharyngeal CancerSquamous Cell Carcinoma of the Oropharynx

Single center, non-randomized Phase II study enrolling Stage I-II p16+ oropharyngeal cancer patients to one of two de-escalation treatment paradigms: (1) receive surgery followed by observation or risk-adjusted adjuvant radiation (+/-chemo), or (2) individualized adaptive definitive chemoradiation (CRT).

Recruiting31 enrollment criteria

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis,...

AL Amyloidosis

The purpose of this study is to determine the event-free survival (EFS) after 3-6 versus 18 cycles of daratumumab maintenance following 6 cycles induction of daratumumab-CyBorD in newly diagnosed AL amyloidosis.

Recruiting42 enrollment criteria

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902),...

CarcinomaRenal Cell

The goal of this China extension study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in Chinese participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.

Recruiting27 enrollment criteria
1...121314...6459

Need Help? Contact our team!


We'll reach out to this number within 24 hrs